Bulumtatug fuvedotin

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameBulumtatug fuvedotin
Drug Alias NameBFv9MW28219MW-28219-MW28219-MW-2821
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-NECTIN4Apoptosis stimulantsMitosis inhibitors +[4] 
TargetsNectin-4Tubulin
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsUrologic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMabwell (Shanghai) Bioscience Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesThe Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical SchoolJiangsu Maiweikang New Drug R & D Co LtdMabwell (Shanghai) Bioscience Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsUrologic Neoplasms +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A